Previous close | 4.6000 |
Open | 4.6900 |
Bid | 4.7500 x 100 |
Ask | 4.9900 x 100 |
Day's range | 4.6100 - 4.9900 |
52-week range | 1.8200 - 8.7500 |
Volume | |
Avg. volume | 152,878 |
Market cap | 257.893M |
Beta (5Y monthly) | 0.34 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2900 |
Earnings date | 20 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.57 |
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include: H.C. Wainwright 2nd Annual BioConnect Investor ConferenceLocation: The Nasdaq Headquarters, New York CityDate: Monday, May 20th at 2:30pm E.TFormat
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC. Details of the presentatio
Insights into Rani Therapeutics' First Quarter Results and Future Clinical Endeavors